Navigation Links
Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
Date:9/23/2009

RICHMOND, Calif., Sept. 23 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that the US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate an open-label, repeat-dosing Phase 1 clinical trial (SB-728-T-902) of the company's ZFN-based therapeutic, SB-728-T. A single dose Phase 1 clinical study of SB-728-T was initiated in February 2009 and is ongoing at the University of Pennsylvania. Both Phase 1 studies are designed primarily to evaluate the safety and tolerability of this ZFP Therapeutic(TM) approach, however subjects' CD4 T-cell counts, levels of CCR5-modified T-cells and viral burden will also be monitored.

"Opening a second Phase 1 clinical trial of this exciting new approach to HIV/AIDS treatment enables us to expedite clinical and commercial development of SB-728-T. We are very pleased with the FDA's decision enabling us to expand this program and move forward quickly with a repeat-dosing trial," said Dale Ando, M.D., Sangamo's chief medical officer and vice president of therapeutic development.

"The best approach to controlling HIV is by preventing infection of cells in the first place. Since 1996, when CCR5 was validated as a target for HIV therapy, the goal has been to recapitulate the naturally-occurring protection against viral infection exhibited by individuals who have the CCR5-delta32 mutation. We have the ability to disrupt the CCR5 gene and make human T-cells resistant to infection by CCR5-specific strains of HIV. In this trial we will be evaluating SB-728-T in subjects that have well-controlled levels of virus but have sub-optimal recovery of CD-4+ T-cell counts despite long-term triple drug therapy. This group represents approximately thirty per
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech
2. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
3. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
4. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
5. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
6. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
7. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
8. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
9. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
10. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
11. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 3SBio Inc. (NASDAQ: SSRX ... China -based biotechnology company focused on ... today that, at an extraordinary general meeting held ... favor of the proposal to authorize and approve ... dated February 8, 2013, among Decade Sunshine Limited, ...
(Date:5/23/2013)... Corporation (NYSE: HAE ) announced today that ... present at The Deutsche Bank 38 th Annual dbAccess ... on May 29, 2013 at 1:30pm Eastern time.  ... may access Mr. Lindop,s presentation live via webcast at: ... (NYSE: HAE ) is a global healthcare company ...
(Date:5/23/2013)... , May 23, 2013  TeamHealth Medical ... nurse triage and nurse advice lines, announces its ... comprising physician, nursing and administrative leaders, provides clinical ... quality and cost-effective services for hospital clients, physician ... national healthcare system evolves, it,s imperative to continuously ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3TeamHealth Medical Call Center Forms Clinical Advisory Committee 2
... 27, 2011 Ameritox (SM), the nation,s leader in ... Statement for the Record for the Congressional hearing on ... D Program," pointing to medication monitoring as a potential ... diversion and aiding in lowering national healthcare costs. The ...
... China, Oct. 27, 2011 /PRNewswire-Asia/ -- China Kanghui Holdings ... a leading domestic developer, manufacturer and marketer of orthopedic ... to release third quarter 2011 financial results on November ... will hold a corresponding conference call and live webcast ...
Cached Medicine Technology:Ameritox Supports Federal Implementation of Medication Monitoring for Chronic Pain Patients 2Ameritox Supports Federal Implementation of Medication Monitoring for Chronic Pain Patients 3China Kanghui Holdings to Report Third Quarter 2011 Financial Results 2
(Date:5/25/2013)... According to an article in the June ... nearly 30 million Americans tan indoors each year and an ... knowing the health risks. New research suggests that UV ... on the brains of some tanners (Go to goo.gl/hdwnz). ... I can’t say that I fully support this contention from ...
(Date:5/25/2013)... Dr. Leslie Gerstman announced today ... lift skin on the neck, on the brow and under ... Aesthetics. , Ultherapy is a non-surgical procedure for the face ... to lift the skin over time. The use of FDA-cleared ... and then treat the deepest support layers of the skin ...
(Date:5/25/2013)... 2013 A disorder of the nerves, ... neuropathy. According to neuropathy expert doctor Helen C Lin, ... that the disorder affects almost 50% of all Diabetic ... Diabetes. The high blood sugar levels in the body ... from it usually tend to have abnormally high blood ...
(Date:5/25/2013)... The report “Global Food Encapsulation Market (2012 – ... Materials, Packaging, & Geography: Trends & Forecasts” defines ... analysis and forecasting of the global revenue for ... restraining factors for the global food encapsulation markets ... market is segmented and revenue are forecasted on ...
(Date:5/25/2013)... 25, 2013 Absolute Surgical Specialists, serving Sun ... the NALA’s businesses throughout the country participating in Shop Local ... in the nationwide event as he understands what military families ... the Army. He said, “I wanted to give something back, ... but I live here too.” , Shop Local for a ...
Breaking Medicine News(10 mins):Health News:Sun Damage – Are UV Rays Addictive? 2Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2Health News:Diabetic Neuropathy treatment hits new grounds- Neuracel launches the complete natural treatment 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 3Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2
... ... HIV STOPS WITH US",is the message of ... across,the country including: Boston, Long Beach and Alameda ... positive people, and a,wide spectrum of HIV negative ... providers and partners talking about real issues., ...
... using widely available and inexpensive ultrasound imaging could help ... or other adverse cardiovascular events, according to a study ... Radiology . , Researchers performed ultrasound imaging on the ... at high risk for cardiovascular disease. Of those, ultrasound ...
... reduces bleeding problems, study finds , , MONDAY, Aug. 18 (HealthDay ... wrist rather than the groin reduces the incidence of bleeding ... using the radial artery in the wrist, is not widely ... almost 600,000 catheterizations in a national database, said a report ...
... Arizona hospitals can access the new AzHHA pharmacy benefit ... immediately see improvements to their bottom ... created and is,supported by the leading pharmacy benefit consulting ... rebate,reimbursements, implementation credits and many other options not typically,available ...
... 18 Today a representative of the,Executive Board ... Local,6434 ("ULTCW") filed a letter of complaint with ... the letter written to President Stern and the ... Vice President of ULTCW and,member of its Executive ...
... Aug. 18 Actavis Group, the,international generic ... approval from the U.S. Food & Drug ... 300mg. Distribution,of the product will commence immediately., ... in,300mg strength, are the generic equivalent of ...
Cached Medicine News:Health News:New HIV Prevention/Anti-Stigma Campaign Featuring HIV Positive & Negative Persons 'TOGETHER' Launches Across the Nation 2Health News:Ultrasound used to predict heart attack risk 2Health News:Reaching the Heart Through the Wrist 2Health News:Reaching the Heart Through the Wrist 3Health News:Arizona Hospital and Healthcare Association Teams Up with ARMSRx to Bring Cost Savings to Hospitals 2Health News:Actavis Receives Approval of Generic Wellbutrin XL(R) 300mg in the U.S. 2
Hubbed drains are made of translucent silicone and include a full-length X-ray opaque stripe....
Siliconized PVC drains...
Bard® Channel Drain...
Used for placement of cholangiography catheters and other instruments. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: